Home › NDC Lookup › RxCUI directory › RxCUI 905162

Olsalazine sodium 250 MG Oral Capsule — RxCUI 905162

RxNorm drug concept · Semantic clinical drug
RxCUI 905162 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI905162
Official nameOlsalazine sodium 250 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Olsalazine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Dipentum is used to keep ulcerative colitis in remission — meaning it helps prevent your symptoms from coming back after they've been controlled. It's prescribed specifically for p...
  • What exactly is Dipentum for, and why was I prescribed it instead of another medication?
  • Dipentum capsules are taken twice daily by mouth. The label doesn't specify taking them with food, so follow whatever instructions your prescriber gave you. One thing that is impor...
  • How should I take these capsules — do I need to take them with food?
📖 Read our full Olsalazine guide →

🕸️ Concept Web — How Olsalazine sodium 250 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Olsalazine sodium 250 MG Oral Capsule RxCUI 905162

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Olsalazine 32385
    • Olsalazine sodium 104123
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Dipentum 49131
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Olsalazine Oral Capsule 373143
    • Olsalazine sodium Oral Capsule 2648476
    • Olsalazine Oral Product 1159564
    • Olsalazine Pill 1159565
    • Olsalazine sodium Oral Product 2662100
    • Olsalazine sodium Pill 2659934
    • Olsalazine Oral Capsule [Dipentum] 366216
    • Olsalazine sodium Oral Capsule [Dipentum] 2654775
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Olsalazine sodium 250 MG SCDC · 905161
  • Olsalazine Oral Capsule SCDF · 373143
  • Olsalazine sodium Oral Capsule SCDFP · 2648476
  • Olsalazine Oral Product SCDG · 1159564
  • Olsalazine Pill SCDG · 1159565
  • Olsalazine sodium Oral Product SCDGP · 2662100
  • Olsalazine sodium Pill SCDGP · 2659934

Brand-Name Concepts

  • Olsalazine sodium 250 MG Oral Capsule [Dipentum] SBD · 905164
  • Olsalazine sodium 250 MG [Dipentum] SBDC · 905163
  • Olsalazine Oral Capsule [Dipentum] SBDF · 366216
  • Olsalazine sodium Oral Capsule [Dipentum] SBDFP · 2654775
  • Dipentum Oral Product SBDG · 1171722
  • Dipentum Pill SBDG · 1171723
  • Dipentum BN · 49131

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 905162 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00037-6860-10 100 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC (0037-6860-... Dipentum Viatris Specialty LLC 2015-05-15
Observed labelers: Viatris Specialty LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$15.6962
Range $15.6962–$15.6962 · middle 50% $15.6962–$15.6962 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.